Interestingly, the findings indicate a potential benefit of higher VC intake for CRC patients with KRAS- or BRAF-mutated tumors, aligning with laboratory evidence and suggesting new avenues for personalized nutrition strategies in CRC management. Here, KRAS is linked to colorectal carcinoma.